［1］ SEHN LH,SALLES G.Diffuse large B-cell lymphoma［J］.N Engl J Med,2021,384(9):842-858.
［2］ WRIGHT GW,HUANG DW.A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications［J］.Cancer Cell,2020,37(4):551-568.
［3］ CABANILLAS F,SHAH B.Advances in diagnosis and management of diffuse large B-cell lymphoma ［J］.Clinical Lymphoma Myeloma and Leukemia,2017,17(12):783-796.
［4］ XIA WK,LIN QF,SHEN D,et al.Prognostic significance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma:a systematic review and meta-analysis ［J］.FEBS Open Bio,2016,6(6):558-565.
［5］ CASTELLINO A,PEDERSON LD,RISTOW KM,et al.Lenalidomide in combination with standard R-CHOP overcomes the negative prognostic value of peripheral blood absolute lymphocyte/monocyte ratio at diagnosis and during treatment in patients with diffuse large B-cell lymphoma ［J］.Blood,2018,132(Suppl 1):4139.
［6］ OTT G,ZIEPERT M,KLAPPER W,et al.Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL［J］.Blood,2010,116(23):4916-4925.
［7］ DE GROEN RAL,SCHRADER AMR,KERSTEN MJ,et al.MYD88 in the driver's seat of B-cell lymphomagenesis:from molecular mechanisms to clinical implications ［J］.Haematologica,2019,104(12):2337-2348.
［8］ DAVIS RE,NGO VN,LENZ G,et al.Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma ［J］.Nature,2010,463(7277):88-92.
［9］ PASQUALUCCI L,ZHANG B.Genetic drivers of NF-κB deregulation in diffuse large B-cell lymphoma ［J］.Seminars in Cancer Biology,2016,39:26-31.
［10］ PASQUALUCCI L,DALLA-FAVERA R.Genetics of diffuse large B-cell lymphoma ［J］.Blood,2018,131(21):2307-2319.
［11］ DE MIRANDA NF,GEORGIOU K,CHEN L,et al.Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients ［J］.Blood,2014,124(16):2544-2553.
［12］ SNEERINGER CJ,SCOTT MP,KUNTZ KW,et al.Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas ［J］.Proc Natl Acad Sci USA,2010,107(49):20980-20985.
［13］ MORIN RD,ASSOULINE S,ALCAIDE M,et al.Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas ［J］.Clin Cancer Res,2016,22(9):2290-2300.
［14］ VERMAAT JS,SOMERS SF,DE WREEDE LC,et al.MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis ［J］.Haematologica,2020,105(2):424-434.
［15］ SEHN LH,BERRY B,CHHANABHAI M,et al.The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP［J］.Blood,2007,109(5):1857-1861.
［16］ NYMAN H,JERKEMAN M,KARJALAINEN-LINDSBERG ML,et al.Bcl-2 but not FOXP1,is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas ［J］.Eur J Haematol,2009,82(5):364-372.
［17］ YOON DH,CHOI DR,AHN HJ,et al.Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP［J］.Eur J Haematol,2010,85(2):149-157.
［18］ MORTON LM,SLAGER SL,CERHAN JR,et al.Etiologic heterogeneity among non-Hodgkin lymphoma subtypes:the InterLymph Non-Hodgkin Lymphoma Subtypes Project ［J］.J Natl Cancer Inst Monogr,2014,2014(48):130-144.
［19］ KIM DH,BAEK JH,CHAE YS,et al.Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma ［J］.Leukemia,2007,21(10):2227-2230.
［20］ FRUEHAUF S,TRICOT G.Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes ［J］.Biol Blood Marrow Transplant,2010,16(12):1629-1648.
［21］ WILCOX RA,WADA DA,ZIESMER SC,et al.Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells ［J］.Blood,2009,114(14):2936-2944.
［22］ PORRATA LF,RISTOW K,COLGAN JP,et al.Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma ［J］.Haematologica,2012,97(2):262-269.
［23］ SUN F,ZHU J,LU S,et al.An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era ［J］.BMC Cancer,2018,18(1):5.
［24］ WILCOX RA,RISTOW K,HABERMANN TM,et al.The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma ［J］.Leukemia,2011,25(9):1502-1509.
［25］ WATANABE R,TOMITA N,ITABASHI M,et al.Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era ［J］.Eur J Haematol,2014,92(3):204-210.
［26］ PORRATA LF,INWARDS DJ,ANSELL SM,et al.Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B cell lymphoma ［J］.Biol Blood Marrow Transplant,2014,20(11):1804-1812.
［27］ REDDY N,HERNANDEZ-ILIZALITURRI EJ,DEEB G,et al.Immunomodulatory drugs stimulate natural killer-cell function,alter cytokine production by dendritic cells,and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo［J］.British Journal of Haematology,2007,140(1):36-45.
［28］ ZHU YX,BRAGGIO E,SHI CX,et al.Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide ［J］.Blood,2011,118(18):4771-4779.
［29］ DALL' OZZO S,TARTAS S,PAINTAUD G,et al.Rituximab-dependent cytotoxicity by natural killer cells:influence of FCGR3A polymorphism on the concentration-effect relationship ［J］.Cancer Research,2004,64(13):4664-4669.
［30］ LU L,PAYVANDI F,WU L,et al.The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions ［J］.Microvascular Research,2009,77(2):78-86.
［31］ VITOLO U,CHIAPPELLA A,FRANCESCHETTI S,et al.Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma:results of the REAL07 open-label,multicentre,phase 2 trial［J］.The Lancet Oncology,2014,15(7):730-737.
［32］ COIFFIER B,THIEBLEMONT C,VAN DEN NESTE E,et al.Long-term outcome of patients in the LNH-98.5 trial,the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients:a study by the Groupe d' Etudes des Lymphomes de l'Adulte ［J］.Blood,2010,116(12):2040-2045.